Medical Management of Coronary Artery Disease: An Update

Abstract

Chronic coronary artery disease (CAD) remains a leading cause of global morbidity and mortality, necessitating a nuanced approach to long-term management. While revascularization strategies play a crucial role in select high-risk patients, optimal medical therapy (OMT) is the foundation of care for most individuals with stable disease. This review critically appraises contemporary pharmacological strategies for CAD, integrating the latest information from randomized trials and guideline-directed recommendations. Antihypertensive therapy, particularly renin–angiotensin system inhibitors and beta-blockers, remains central to reducing myocardial workload and preventing adverse cardiovascular events. Lipid-lowering agents, including high-intensity statins, ezetimibe, PCSK9 inhibitors, and inclisiran, have redefined risk stratification by demonstrating incremental reductions in low-density lipoprotein and atherosclerotic progression and event recurrence. The emergence of novel antidiabetic agents—SGLT2 inhibitors and GLP-1 receptor agonists—has expanded the therapeutic landscape, offering cardioprotective benefits independent of glycemic control. Additionally, the growing recognition of inflammation as a driver of CAD progression has led to the exploration of anti-inflammatory agents such as colchicine and interleukin-1 beta inhibitors. Landmark trials, including COURAGE, ISCHEMIA, and FREEDOM, reaffirm the noninferiority of OMT to revascularization in stable CAD, underscoring the need for an individualized approach. Future directions encompass precision medicine, artificial intelligence-driven risk stratification, and gene-based interventions, which may redefine therapeutic paradigms in CAD management.

Chronic coronary artery disease (CAD) remains the leading cause of cardiovascular morbidity and mortality worldwide, contributing to millions of deaths annually. ^{1 2} Despite advancements in interventional cardiology and surgical techniques, CAD continues to impose a significant burden on health care systems due to its progressive nature and the high prevalence of modifiable risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking. ^{3 4} The increasing global incidence of CAD underscores the urgent need for effective long-term management strategies that not only alleviate symptoms but also modify the disease trajectory and reduce the risk of major adverse cardiovascular events (MACE). ^{4 5 6}

The pathophysiology of stable ischemic heart disease (SIHD) is driven by the gradual accumulation of atherosclerotic plaques within the coronary arteries, leading to luminal narrowing, endothelial dysfunction, and impaired myocardial perfusion. ^{7 8} Unlike acute coronary syndromes (ACS), which often result from plaque rupture and acute thrombosis, SIHD is characterized by stable yet progressive plaque formation, with inflammation playing a central role in disease progression. ^{9 10 11} Atherothrombosis, endothelial dysfunction, and oxidative stress collectively contribute to recurrent ischemic events, heart failure, and sudden cardiac death. ^{12 13} Over time, compensatory mechanisms such as collateral vessel formation may partially offset ischemia, but as the disease advances, myocardial oxygen demand eventually surpasses supply, leading to exertional angina, reduced exercise tolerance, and increased cardiovascular risk. ^{14 15} Given this pathophysiological basis, the goal of CAD management extends beyond symptom control to include disease modification through pharmacological intervention aimed at stabilizing plaques, reducing inflammation, preventing thrombosis, and optimizing myocardial perfusion ( Fig. 1 ).

Fig. 1.

Progression of atherosclerosis, from a normal artery to a complete blockage.

Historically, revascularization via percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) was considered the primary strategy for managing CAD. ¹⁶ However, landmark trials have demonstrated that in stable CAD, optimal medical therapy (OMT) alone provides comparable long-term survival outcomes to invasive procedures, challenging the conventional approach of prioritizing revascularization. ¹⁷ These studies have shifted the paradigm toward aggressive risk factor modification as the cornerstone of CAD management, with pharmacological therapy playing a central role in slowing disease progression and preventing ischemic events. ^{4 18} The evidence overwhelmingly supports the use of lipid-lowering agents, antihypertensives, antiplatelet therapy, and novel cardioprotective agents as first-line interventions, reserving revascularization for patients with high-risk anatomical features, refractory symptoms, or acute events.

Contemporary guideline-based management of CAD follows a structured, stepwise pharmacological approach aimed at optimizing cardiovascular risk reduction. The 2023 American College of Cardiology (ACC) and American Heart Association (AHA) guidelines continue to emphasize aggressive lipid-lowering strategies, with high-intensity statins as first-line therapy and the addition of ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for patients who fail to achieve target low-density lipoprotein cholesterol (LDL-C) levels. ¹⁹ Blood pressure control remains crucial, with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) recommended in patients with hypertension, diabetes, or heart failure, whereas β-blockers are standard post-myocardial infarction (MI). ^{20 21 22 23} Antiplatelet therapy remains the foundation of secondary prevention, with aspirin being universally recommended and dual antiplatelet therapy (DAPT) indicated for select patients post-PCI or ACS. ^{22 23} In patients with diabetes, the emergence of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) has revolutionized risk reduction strategies, offering significant cardiovascular benefits beyond glycemic control. Additionally, the role of inflammation in CAD has gained increasing recognition, with recent studies supporting the use of anti-inflammatory agents such as colchicine and interleukin-1 beta (IL-1β) inhibitors in select high-risk patients. ^{10 24} Given the growing body of evidence supporting medical therapy as the primary strategy for chronic CAD, this review aims to provide a comprehensive analysis of pharmacological management. By integrating findings from landmark clinical trials, updated guideline recommendations, and emerging research, this paper highlights the crucial role of medical therapy in reducing cardiovascular morbidity and mortality.

Search Strategy and Selection Criteria

A comprehensive literature search was conducted using MEDLINE (PubMed), Embase, and the Cochrane Library to identify relevant studies published between January 2000 and January 2025. The search was limited to English language publications and focused on randomized controlled trials and clinical guidelines addressing the medical management of chronic CAD. The search terms included chronic coronary artery disease, medical management of coronary artery disease, hypertension in coronary artery disease, diabetes and coronary artery disease, lipid-lowering therapy in coronary artery disease, hyperlipidemia in coronary artery disease, antiplatelet therapy, anticoagulation in coronary artery disease, and inflammatory disease and coronary artery disease .

Studies were included if they evaluated pharmacological interventions for chronic CAD, with a particular focus on risk factor modification, antihypertensive therapy, lipid-lowering agents, antithrombotic regimens, and emerging cardioprotective drugs. Clinical guidelines from the ACC and the AHA (2023) were reviewed to ensure alignment with the latest recommendations.

Studies were excluded if they primarily focused on ACS, interventional procedures such as PCI or CABG without discussion of medical therapy, or European guideline recommendations published by the European Society of Cardiology. Additional sources were identified through manual screening of reference lists from key articles and recent conference proceedings of the ACC and the AHA to capture the most up-to-date evidence.

Coronary Artery Disease: Pathophysiology and Management

Hypertension

Hypertension is a major modifiable risk factor for CAD, contributing to the progression of atherosclerosis, left ventricular hypertrophy, and increased myocardial oxygen demand. Patients with CAD and concomitant hypertension have a heightened risk of stroke, MI, and heart failure. The 2023 ACC/AHA guidelines recommend a target blood pressure of less than 130/80 mm Hg in CAD patients, often necessitating combination therapy ^{19 25} ( Table 1 ).

Table 1. Pharmacological management of coronary artery disease across comorbid conditions.

Condition	Drug class	Example agents	Primary cardiovascular benefit	Supporting trials
Hypertension	ACE inhibitors	Ramipril, perindopril	Reduction in MI, stroke, and mortality	HOPE, EUROPA
	Calcium channel blockers	Amlodipine, diltiazem	Reduction in CV events in CAD patients	CAMELOT
	Thiazide diuretics	Chlorthalidone, hydrochlorothiazide	Reduction in BP and stroke risk	ALLHAT
	Mineralocorticoid receptor antagonists	Spironolactone, eplerenone	Reduction in BP in resistant hypertension	PATHWAY-2
Diabetes mellitus	SGLT2 inhibitors	Empagliflozin, dapagliflozin	Reduction in CV mortality and HF hospitalizations	EMPA-REG, CANVAS, DECLARE-TIMI 58
	GLP-1 RAs	Liraglutide, semaglutide	Reduction in CV death and stroke risk	LEADER, SUSTAIN-6
	Metformin	Metformin	Foundational glycemic control, modest CV benefit	UKPDS
	DPP-4 inhibitors	Sitagliptin, linagliptin	Neutral CV effect	TECOS
	Sulfonylureas	Glimepiride, gliclazide	Effective glucose lowering, neutral CV risk	CAROLINA
	Insulin	Insulin glargine	Necessary in advanced diabetes, neutral CV effect	ORIGIN
Hyperlipidemia	Statins (high intensity)	Atorvastatin, rosuvastatin	Reduction in MI, stroke, mortality	FOURIER, IMPROVE-IT
	PCSK9 inhibitors	Evolocumab, alirocumab	Additional LDL-C lowering, CV event reduction	FOURIER, ODYSSEY OUTCOMES
	Ezetimibe	Ezetimibe	LDL-C lowering, adjunct to statins	IMPROVE-IT
	Bempedoic acid	Bempedoic acid	LDL-C reduction in statin-intolerant patients	CLEAR Outcomes
	Icosapent ethyl	Icosapent ethyl	Reduction in CV events, TG lowering	REDUCE-IT
Antiplatelet/anticoagulation	Aspirin	Low-dose aspirin	Reduction in thrombotic events	COMPASS
	P2Y12 inhibitors	Clopidogrel, ticagrelor, prasugrel	Reduction in MI, stroke, and stent thrombosis	PLATO, TRITON-TIMI 38
	Dual antiplatelet therapy (DAPT)	Aspirin + P2Y12 inhibitor	Enhanced thrombotic protection post-PCI	CURE
	Direct oral anticoagulants (DOACs)	Rivaroxaban, dabigatran, apixaban	Reduction in thromboembolic events in AF + CAD	AUGUSTUS, RE-DUAL PCI
	Prolonged antiplatelet therapy	Ticagrelor (beyond 12 mo)	Reduced recurrent MI, increased bleeding risk	PEGASUS-TIMI 54
Inflammatory disease in CAD	Statins	Rosuvastatin, atorvastatin	Reduction in CV events, anti-inflammatory properties	JUPITER, TRACE RA
	RAAS inhibitors	ACE inhibitors, ARBs	BP control, endothelial protection	Observational Data
	TNF inhibitors	Adalimumab, infliximab	Potential CV risk reduction	Observational Data
	IL-1β inhibitors	Canakinumab	Reduction in MACE	CANTOS
	Methotrexate	Methotrexate	Possible CV benefit in RA	CIRT
	Colchicine	Colchicine	Reduction in post-MI CV events	COLCOT

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CAD, coronary artery disease; CV, cardiovascular; IL-1β, interleukin-1 beta; MACE, major adverse cardiovascular event; MI, myocardial infarction; PCI, percutaneous coronary intervention; RA, receptor agonist; RAAS, renin–angiotensin–aldosterone system; TNF, tumor necrosis factor.

Pharmacological management begins with first-line therapy, which includes ACE inhibitors or ARBs. These agents not only lower blood pressure but also mitigate endothelial dysfunction and vascular remodeling, leading to a reduction in cardiovascular events. ²⁶ The HOPE trial demonstrated that ramipril significantly reduced MI, stroke, and cardiovascular death in high-risk CAD patients, whereas the EUROPA trial supported similar benefits with perindopril. ^{27 28} Beta-blockers are also considered first-line agents, particularly in post-MI patients and those with heart failure, as they reduce myocardial oxygen demand, prevent arrhythmic events, and improve survival.

For patients requiring additional blood pressure control, second-line therapy consists of calcium channel blockers and thiazide diuretics, which serve as effective adjunct therapies. Calcium channel blockers, particularly dihydropyridines such as amlodipine, have demonstrated efficacy in reducing cardiovascular events in CAD patients, as shown by the CAMELOT trial, which found that amlodipine significantly reduced MACE. ²⁹ Thiazide diuretics, including chlorthalidone and hydrochlorothiazide, provide additional antihypertensive effects and have been particularly beneficial in resistant hypertension. ³⁰ The ALLHAT trial confirmed that chlorthalidone significantly reduces cardiovascular morbidity and mortality, particularly in older patients and those with multiple risk factors. ³¹ In cases of resistant hypertension or heart failure, third-line therapy includes mineralocorticoid receptor antagonists such as spironolactone, which offer further blood pressure control. The PATHWAY-2 trial demonstrated that spironolactone was superior to placebo in lowering blood pressure in patients with resistant hypertension. In select cases, alpha-blockers and direct vasodilators may be used, particularly in patients who remain hypertensive despite multiple pharmacological interventions or those with specific conditions such as pheochromocytoma. ^{32 33}

The pharmacological management of hypertension in CAD should be individualized based on patient characteristics, comorbid conditions, and clinical presentation. First-line therapy, including ACE inhibitors or ARBs and beta-blockers, remains the foundation of treatment, with second-line agents such as calcium channel blockers and thiazide diuretics providing additional control when needed. In cases of resistant hypertension, third-line agents such as mineralocorticoid receptor antagonists may be considered. By optimizing blood pressure control and addressing modifiable risk factors, clinicians can significantly reduce cardiovascular morbidity and mortality in patients with CAD.

Diabetes Mellitus

Diabetes mellitus, particularly type 2 diabetes, is a significant contributor to adverse cardiovascular outcomes in CAD. The presence of diabetes accelerates atherosclerosis, promotes endothelial dysfunction, and increases platelet reactivity, thereby elevating the risk of MACE. ^{34 35} Patients with CAD and diabetes experience higher rates of MI, stroke, and cardiovascular mortality, necessitating a targeted therapeutic approach that extends beyond glycemic control to include cardiovascular risk reduction.

The pharmacological management of diabetes in CAD has evolved with the emergence of cardioprotective agents that provide substantial cardiovascular benefits independent of glucose lowering. First-line therapy includes SGLT2 inhibitors, which have demonstrated robust cardiovascular protection. ^{36 37} The EMPA-REG OUTCOME trial showed that empagliflozin reduced cardiovascular mortality by 38% and heart failure hospitalizations by 35% in diabetic patients with established CAD. ³⁸ Similar findings were found in the DECLARE-TIMI 58 trials, reinforcing the role of SGLT2 inhibitors in reducing heart failure-related outcomes and cardiovascular mortality. ³⁹ As a result, the 2023 ACC/AHA guidelines recommend SGLT2 inhibitors as a primary therapy in diabetic patients with CAD, irrespective of baseline glycemic control.

GLP-1 RAs also represent an essential component of first-line therapy due to their atherosclerotic cardiovascular disease risk reduction properties. ^{40 41} The LEADER trial demonstrated that liraglutide reduced cardiovascular mortality by 22%, whereas the SUSTAIN-6 trial found that semaglutide significantly decreased nonfatal stroke risk in diabetic patients with CAD. ^{42 43} The cardiovascular benefits of GLP-1 RAs are attributed to their anti-inflammatory effects, weight reduction, and improvements in endothelial function. These agents are recommended alongside SGLT2 inhibitors to provide comprehensive cardiovascular protection in diabetic patients with CAD. ⁴³

Second-line therapy includes metformin, which remains the cornerstone of glycemic control in diabetes. While metformin has demonstrated favorable cardiovascular effects in subgroup analyses, its direct impact on major cardiovascular events is less pronounced compared with SGLT2 inhibitors and GLP-1 RAs. For patients requiring intensified glycemic management, third-line therapy includes insulin and sulfonylureas, which are used selectively due to their potential for hypoglycemia and weight gain. While these agents effectively reduce blood glucose levels, they have not demonstrated the same cardiovascular benefits as SGLT2 inhibitors or GLP-1 RAs. The CAROLINA trial found that glimepiride had a neutral cardiovascular risk profile compared with linagliptin, indicating its safety but without cardiovascular protection. ⁴⁴ The ORIGIN trial examined insulin glargine in patients with prediabetes and early diabetes and found no significant reduction in cardiovascular events, confirming that insulin remains essential for glycemic control but lacks cardiovascular benefits. ⁴⁵ Insulin therapy is typically reserved for advanced diabetes with significant beta-cell dysfunction, whereas sulfonylureas, such as glimepiride and gliclazide, remain an option in resource-limited settings where cost considerations dictate treatment selection. ⁴⁶

Beyond pharmacological therapy, diabetic patients with CAD require individualized revascularization strategies. The BARI-2D trial found that in diabetic patients with stable CAD, intensive medical therapy provided comparable survival outcomes to early revascularization. ⁴⁷ However, the FREEDOM trial established that in diabetics with multivessel CAD, CABG significantly reduced mortality and MI rates compared with PCI. ⁴⁸ As a result, current guidelines recommend CABG over PCI in diabetic patients with complex CAD, particularly when the left anterior descending artery is involved.

The management of diabetes in CAD has shifted toward prioritizing agents with demonstrated cardiovascular benefits. First-line therapy with SGLT2 inhibitors and GLP-1 RAs is now recommended to reduce cardiovascular mortality and heart failure risk, whereas metformin remains a fundamental glycemic agent. ⁴⁹ Second-line therapies such as DPP-4 inhibitors offer neutral cardiovascular effects but serve as alternatives for glycemic control. Third-line therapies, including insulin and sulfonylureas, are reserved for select cases where other agents are insufficient. Management of diabetes in CAD extends beyond pharmacotherapy and procedural decisions. Lifestyle modifications, including dietary adjustments, weight management, and physical activity, remain central to the management of diabetes in CAD. While intensive glucose control was historically prioritized, aggressive glycemic targets do not necessarily translate to reduced macrovascular events and may increase the risk of hypoglycemia-related complications. ⁵⁰ The current emphasis is on a balanced approach that integrates pharmacotherapy with lifestyle interventions to achieve optimal cardiovascular risk reduction ( Fig. 2 ).

Fig. 2.

Impact of lifestyle modifications on cardiovascular risk reduction in coronary artery disease (CAD) Management. This radar chart illustrates the relative impact of key lifestyle interventions on reducing cardiovascular risk in patients with chronic CAD. Data are based on clinical trial evidence and guideline recommendations.

Hyperlipidemia

Dyslipidemia is a key driver of atherosclerosis and CAD, contributing to plaque formation, vascular inflammation, and cardiovascular events. ⁵¹ Elevated levels of LDL-C accelerate plaque development, while reductions in high-density lipoprotein cholesterol impair reverse cholesterol transport. Hypertriglyceridemia further exacerbates cardiovascular risk by promoting endothelial dysfunction and increasing proinflammatory mediators. ^{52 53} Given the established causal relationship between dyslipidemia and CAD, lipid-lowering therapy is a fundamental component of secondary prevention strategies.

The pharmacological management of hyperlipidemia in CAD prioritizes LDL-C reduction as the primary target. First-line therapy consists of high-intensity statins, consistently demonstrating reductions in cardiovascular events and mortality. ⁵⁴ The FOURIER trial showed that achieving very low LDL-C levels significantly reduced MACE, reinforcing the importance of aggressive lipid lowering. ⁵⁵ The IMPROVE-IT trial proved that adding ezetimibe to statin therapy led to a further reduction in cardiovascular risk, supporting combination therapy in high-risk patients who do not achieve LDL-C targets with statins alone. ⁵⁶

For patients who require additional LDL-C lowering despite maximally tolerated statin therapy, second-line agents include PCSK9 inhibitors such as evolocumab and alirocumab. Inclisiran, a siRNA-based therapy, effectively inhibits PCSK9 expression, offering sustained lipid control with just two annual doses. ⁵⁷ The FOURIER and ODYSSEY OUTCOMES trials demonstrated that PCSK9 inhibitors significantly reduce cardiovascular events when added to statin therapy. ^{55 58} These agents are particularly beneficial for patients with familial hypercholesterolemia or those with persistently high LDL-C levels despite optimized statin therapy. Bempedoic acid, an ATP citrate lyase inhibitor, provides an alternative for patients who are statin-intolerant or require additional LDL-C reduction. ⁵⁹

Hypertriglyceridemia is an independent risk factor for cardiovascular events, necessitating targeted management in high-risk CAD patients. Icosapent ethyl, a purified eicosapentaenoic acid derivative, was evaluated in the REDUCE-IT trial, which found a significant reduction in cardiovascular events among statin-treated patients with hypertriglyceridemia. ⁶⁰ Given these findings, icosapent ethyl is recommended as adjunctive therapy in patients with persistently elevated triglycerides despite statin therapy. Lipid-lowering therapy in CAD has evolved to emphasize intensive LDL-C reduction, particularly with high-intensity statins as first-line agents. For patients who do not achieve LDL-C targets, PCSK9 inhibitors and ezetimibe serve as effective second-line agents. ⁶¹ In patients with persistent hypertriglyceridemia despite statin therapy, icosapent ethyl offers additional cardiovascular protection. The integration of pharmacological and lifestyle interventions remains crucial in optimizing lipid control and reducing long-term cardiovascular risk in CAD patients. Beyond pharmacological therapy, lifestyle interventions, including dietary modifications, weight management, and regular physical activity, remain essential in hyperlipidemia management. Adherence to a Mediterranean diet, which emphasizes a high intake of unsaturated fats, fiber, and omega-3 fatty acids, has been associated with reduced cardiovascular mortality. ⁶² Smoking cessation and moderation of alcohol intake further contribute to lipid profile improvement and cardiovascular risk reduction.

Antiplatelet and Anticoagulant Therapy

Thrombotic complications play a central role in the pathophysiology of CAD, necessitating antithrombotic therapy for both primary and secondary prevention of cardiovascular events. Platelet activation and fibrin formation contribute to atherothrombosis, which can lead to MI and stroke. The selection of antiplatelet and anticoagulant therapy in CAD is determined by the balance between ischemic protection and bleeding risk, particularly in patients undergoing PCI or those with concomitant atrial fibrillation (AF). ⁶³

Antiplatelet therapy remains the cornerstone of secondary prevention in CAD. First-line therapy consists of aspirin, which irreversibly inhibits cyclooxygenase-1 and thromboxane A2 production, reducing platelet aggregation. ⁶⁴ The CURE trial demonstrated that DAPT with clopidogrel and aspirin significantly reduced MACE in patients with ACS. ⁶⁵ For stable CAD, the COMPASS trial showed that low-dose rivaroxaban in combination with aspirin further reduced cardiovascular mortality compared with aspirin alone. In patients at high ischemic risk, potent P2Y12 inhibitors such as ticagrelor and prasugrel provide superior thrombotic protection. ⁶⁶ The PLATO trial confirmed that ticagrelor reduced cardiovascular mortality and MI rates compared with clopidogrel, whereas the TRITON-TIMI 38 trial found that prasugrel was particularly effective in reducing stent thrombosis in PCI-treated patients. ^{67 68}

In patients requiring long-term anticoagulation, particularly those with AF and CAD, direct oral anticoagulants (DOACs) have largely replaced warfarin due to their improved safety profile. Second-line therapy includes the combination of anticoagulation with a single antiplatelet agent rather than prolonged DAPT to minimize bleeding risk. The AUGUSTUS and RE-DUAL PCI trials demonstrated that rivaroxaban and dabigatran, respectively, in combination with a P2Y12 inhibitor resulted in fewer bleeding complications compared with triple therapy with warfarin, aspirin, and a P2Y12 inhibitor. ^{69 70} The PIONEER AF-PCI trial also confirmed that reduced-dose rivaroxaban plus clopidogrel was superior to warfarin-based triple therapy in terms of bleeding risk while maintaining thrombotic protection. ⁷¹

In high-risk patients requiring prolonged thrombotic protection beyond 1 year, extended-duration antithrombotic strategies have been evaluated. The PEGASUS-TIMI 54 trial found that extended ticagrelor therapy beyond 12 months significantly reduced recurrent cardiovascular events in high-risk post-MI patients. ⁷² However, this benefit came at the cost of increased bleeding, necessitating patient-specific risk stratification.

The selection of antithrombotic therapy should be individualized based on the patient's ischemic and bleeding risks. Risk scores such as the HAS-BLED and DAPT scores guide treatment duration and intensity. ⁷³ In PCI-treated patients, shorter DAPT durations (3–6 months) have been explored in trials such as TWILIGHT and STOPDAPT-2, confirming that carefully selected patients can discontinue aspirin earlier to minimize bleeding risk while maintaining ischemic protection. ⁷⁴ The management of antiplatelet and anticoagulant therapy in CAD requires a balance between ischemic protection and bleeding risk. First-line therapy remains DAPT with aspirin and a P2Y12 inhibitor, particularly in high-risk patients undergoing PCI. For those requiring long-term anticoagulation, DOACs combined with a P2Y12 inhibitor provide a safer alternative to warfarin-based triple therapy. ⁷⁴ Prolonged antithrombotic therapy beyond 1 year may be beneficial in selected high-risk patients but requires careful assessment of bleeding risk. Individualized therapy based on clinical risk stratification remains essential for optimizing long-term cardiovascular outcomes in CAD patients ( Table 2 ).

Table 2. Comparison of dual antiplatelet therapy strategies in coronary artery disease.

Strategy	P2Y12 inhibitor	Duration	Bleeding risk	Key trials
Standard DAPT	Clopidogrel	6 mo	Moderate	DAPT, CURE
Intensified DAPT	Ticagrelor, prasugrel	>12 mo	High	PEGASUS-TIMI 54
Shortened DAPT	Clopidogrel	3 mo (if high bleeding risk)	Lower	STOPDAPT-2
Aspirin + rivaroxaban	Rivaroxaban (2.5 mg twice a day)	Long term	Moderate	COMPASS

Abbreviation: DAPT, dual antiplatelet therapy.

Rheumatoid and Inflammatory Disease

Chronic inflammatory diseases, such as rheumatoid arthritis (RA) and systemic lupus erythematosus, are associated with a heightened risk of CAD due to persistent systemic inflammation, endothelial dysfunction, and accelerated atherosclerosis. ⁷⁵ Patients with inflammatory conditions experience a disproportionate burden of cardiovascular events independent of traditional risk factors. The interplay between immune-mediated pathways and atherothrombosis necessitates a tailored approach to CAD prevention and management in this high-risk population.

First-line therapy for CAD in inflammatory diseases involves aggressive management of traditional cardiovascular risk factors, including dyslipidemia, hypertension, and diabetes. Statins remain the cornerstone of lipid-lowering therapy, with the JUPITER trial demonstrating that rosuvastatin significantly reduced cardiovascular events in patients with elevated C-reactive protein, highlighting the role of inflammation in atherogenesis. ⁷⁶ The evaluated statin therapy in RA and found a trend toward cardiovascular risk reduction, reinforcing the benefit of lipid control in inflammatory disease populations. Blood pressure control with renin–angiotensin–aldosterone system inhibitors, such as ACE inhibitors and ARBs, is recommended due to their anti-inflammatory and endothelial-protective properties. ²⁰

Second-line therapy includes targeted immunomodulatory strategies aimed at reducing systemic inflammation. Tumor necrosis factor (TNF) inhibitors, commonly used in RA, have demonstrated cardioprotective effects, as shown in observational studies linking TNF inhibition with reduced cardiovascular events. ⁷⁷ The CANTOS trial showed that reducing inflammation with canakinumab, a monoclonal antibody targeting interleukin-1β, resulted in a significant reduction in MACE, independent of lipid lowering. ⁷⁸ Methotrexate, a cornerstone therapy for RA, has been associated with reduced cardiovascular risk, although the CIRT trial found no benefit in nonrheumatic populations, suggesting that its effects may be limited to patients with systemic inflammatory disorders. ⁷⁹

For patients with inflammatory disease and CAD, third-line interventions include antiplatelet therapy and novel anti-inflammatory agents. Aspirin is commonly used in secondary prevention, although its role in primary prevention among patients with inflammatory conditions remains unclear. Emerging therapies targeting interleukin-6 and Janus kinase pathways, such as tocilizumab and tofacitinib, are under investigation for their potential cardiovascular effects. ⁸⁰ The CANTOS trial evaluated canakinumab, an interleukin-1β inhibitor, to reduce residual inflammatory risk in atherosclerotic disease. In contrast, the COLCOT trial tested low-dose colchicine after MI. Together, these studies underscore the growing interest in anti-inflammatory therapies for CAD, particularly in patients with autoimmune or inflammatory conditions. ^{78 81}

Nonpharmacological interventions, including lifestyle modifications and cardiovascular risk assessment, play a critical role in managing CAD in inflammatory disease populations. Regular physical activity, dietary modifications, and smoking cessation are essential components of a comprehensive cardiovascular prevention strategy. Given the increased cardiovascular risk in these patients, routine screening and early intervention remain paramount. The management of CAD in inflammatory diseases requires an integrative approach that targets both traditional cardiovascular risk factors and systemic inflammation. First-line therapy involves optimizing lipid levels, blood pressure, and glucose control, whereas second-line strategies incorporate anti-inflammatory agents such as TNF inhibitors and IL-1β blockade. Third-line options, including colchicine and emerging biologics, may offer additional cardiovascular protection. ^{82 83} Given the complex interplay between inflammation and atherosclerosis, early risk stratification and personalized treatment strategies are critical in improving long-term cardiovascular outcomes in patients with inflammatory diseases and CAD.

Interpretation of Landmark Trials Comparing Medical versus Surgical/Percutaneous Coronary Intervention Management

The comparative effectiveness of OMT, PCI, and CABG in the management of CAD has been rigorously evaluated in clinical trials, shaping contemporary guideline-directed strategies. These landmark studies provide crucial insights into the selection of treatment modalities, emphasizing an individualized approach based on ischemic burden, anatomical complexity, and comorbid conditions.

The COURAGE trial (2007) established that PCI does not confer a survival benefit over OMT alone in stable CAD, as rates of all-cause mortality and MI were comparable between groups. ⁸⁴ However, PCI was associated with greater symptomatic relief from angina, although this benefit diminished over time. These findings positioned OMT as the cornerstone of stable CAD management, reserving PCI primarily for patients with persistent symptoms refractory to pharmacological therapy.

The role of revascularization in diabetic patients with CAD has been further clarified by subsequent trials. BARI-2D (2009) demonstrated that OMT was noninferior to early revascularization in many diabetic patients but that CABG significantly reduced cardiovascular events in those with extensive multivessel disease. ⁴⁷ The FREEDOM trial (2012) provided definitive evidence supporting CABG as the preferred revascularization strategy in diabetics with complex CAD, demonstrating lower rates of mortality and MI compared with PCI, despite an associated increase in stroke risk. These findings reinforced the superior long-term benefit of surgical revascularization in this high-risk subgroup. ⁴⁸

Beyond anatomical considerations, functional lesion assessment has gained increasing importance in guiding revascularization decisions. FAME 2 (2012) demonstrated that fractional flow reserve (FFR)-guided PCI improved quality of life by alleviating symptoms in patients with functionally significant stenoses, although it did not confer a mortality advantage over OMT alone. ⁸⁵ The ISCHEMIA trial (2020) reaffirmed that in patients with moderate-to-severe ischemia, an initial strategy of OMT was as effective as PCI in reducing MACE, with PCI offering symptomatic relief rather than improved survival. ⁸⁶ These findings reinforced the paradigm shift toward prioritizing medical therapy before considering revascularization, except in cases of severe ischemia or refractory symptoms.

In addition to traditional approaches, anti-inflammatory therapy has emerged as a novel adjunct in CAD management. The LoDoCo2 trial (2020) demonstrated that colchicine significantly reduced cardiovascular events in stable CAD patients, providing compelling information for its role as an anti-inflammatory intervention in atherosclerosis. ⁸¹ Conversely, the REVIVED-BCIS2 trial (2022) challenged the utility of PCI in ischemic cardiomyopathy, showing that PCI did not improve survival or left ventricular function in patients with severe left ventricular dysfunction when added to OMT. ⁸⁷

Taken together, these landmark trials underscore the central role of OMT in the management of stable CAD, with PCI reserved primarily for angina relief and CABG favored in patients with diabetes and complex multivessel disease. The contemporary approach to CAD management emphasizes personalized decision-making, integrating disease burden, ischemia severity, functional lesion assessment, and patient comorbidities to optimize long-term outcomes ( Table 3 ).

Table 3. Landmark trials in coronary artery disease management.

Trial Name	Population	Comparison	Key findings	Clinical implications
COURAGE (2007)	2,287 stable CAD patients	PCI + OMT vs. OMT alone	No survival benefit of PCI over OMT	OMT should be first line
BARI-2D (2009)	2,368 diabetics with CAD	PCI vs. CABG vs. OMT	CABG better in diabetics with extensive CAD	CABG preferred in diabetics with multivessel disease
FAME 2 (2012)	1,220 stable CAD patients	PCI + OMT vs. OMT alone	PCI improved quality of life, no mortality benefit	PCI recommended for symptomatic patients after OMT trial
ISCHEMIA (2020)	5,179 moderate-to-severe ischemia	PCI/CABG + OMT vs. OMT alone	No mortality difference, PCI improved angina	OMT is as effective as PCI in stable CAD
LoDoCo2 (2020)	5,522 CAD patients	Colchicine vs. placebo	Reduced CV events in chronic CAD patients	Colchicine is a potential adjunct in CAD therapy
REVIVED-BCIS2 (2022)	700 patients with severe LV dysfunction	PCI + OMT vs. OMT alone	No mortality or functional benefit with PCI	PCI not beneficial for ischemic cardiomyopathy without angina

Abbreviations: CABG, coronary artery bypass grafting; CAD, coronary artery disease; OMT, optimal medical therapy; PCI, percutaneous coronary intervention.

Future Directions and Emerging Therapies

The future of CAD management is evolving towards gene-based therapies, artificial intelligence (AI)-driven risk stratification, and precision medicine, aiming to refine treatment strategies and reduce cardiovascular events beyond current standard therapies. Gene-based interventions, particularly PCSK9 gene silencing, have shown promise in long-term LDL-C reduction. Early research on CRISPR-Cas9 gene editing suggests the potential for permanently modifying lipid metabolism genes such as ANGPTL3, potentially enabling lifelong control of hyperlipidemia. ⁸⁸ While these approaches remain experimental, they hold the potential to redefine the management of atherosclerosis by targeting its molecular underpinnings rather than solely modulating risk factors.

AI is transforming risk stratification and treatment optimization, integrating genetic, biomarker, and imaging data to enhance predictive accuracy beyond traditional tools such as the atherosclerosis cardiovascular disease (ASCVD) risk calculator. AI-enhanced coronary computed tomography angiography is demonstrating superior precision in quantifying coronary plaque burden and predicting future cardiac events. Additionally, AI-driven decision support systems are refining antithrombotic and lipid therapy selection, ensuring tailored treatment strategies based on individual risk profiles. Remote monitoring via AI-powered wearables and mobile health applications is further optimizing disease surveillance and medication adherence. ^{89 90} Meanwhile, precision medicine is advancing pharmacological personalization, leveraging genetic and inflammatory biomarkers to guide targeted interventions such as colchicine and IL-1β inhibitors for residual inflammatory risk. These emerging innovations—gene-based therapies, AI-driven predictive models, and tailored pharmacological strategies—are poised to shift CAD management toward a more personalized, pathophysiology-driven paradigm, improving outcomes through early intervention and individualized care ( Fig. 3 ).

Fig. 3.

Future directions in coronary artery disease (CAD) management. A stepwise transition from traditional CAD management (lifestyle changes, medications, and surgery) to precision medicine, integrating artificial intelligence-driven risk stratification, biomarker-based diagnostics, and gene-based therapies. The timeline illustrates the evolution from generalized treatments to personalized, data-driven approaches, enhancing early detection, risk prediction, and targeted interventions.

Conclusion

The paradigm of chronic CAD management has shifted toward OMT as the foundation of treatment, with trials such as COURAGE, ISCHEMIA, and BARI-2D demonstrating comparable survival outcomes between OMT and revascularization in stable CAD. Guideline-directed management prioritizes strict risk factor control, incorporating renin–angiotensin system inhibitors, β-blockers, statins, SGLT2 inhibitors, GLP-1 RAs, and antithrombotic agents to mitigate cardiovascular risk. In diabetic patients with multivessel disease, FREEDOM and SYNTAX trials support CABG over PCI, reinforcing the need for anatomical complexity assessment when determining revascularization strategies. The addition of PCSK9 inhibitors, dual pathway antithrombotic regimens (aspirin + low-dose rivaroxaban), and anti-inflammatory agents has further expanded treatment options, particularly in high-risk patients. To optimize outcomes, management should emphasize the early initiation of guideline-directed medical therapy alongside strict lipid, glycemic, and blood pressure control in high-risk populations. Integrating biomarker-driven risk assessment and advanced imaging can refine treatment selection, guiding individualized decisions between medical therapy, PCI, and CABG. Patients with diabetes, inflammatory disorders, or residual cardiovascular risk should be prioritized for adjunctive lipid-lowering and anti-inflammatory interventions, such as PCSK9 inhibitors, icosapent ethyl, and IL-1β antagonists. In antithrombotic therapy, dual pathway inhibition may provide greater protection in high-risk patients, while shortened DAPT regimens may be preferable in those with an elevated bleeding risk, aligning with evolving guideline recommendations. Additionally, for patients with complex CAD, particularly those with diabetes, multidisciplinary heart team evaluations using SYNTAX scoring should standardize revascularization decision-making, ensuring optimal procedural selection and long-term outcomes.